Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Nadav Kidron is President and CEO at Oramed Pharmaceuticals. OQRO lists 21 transactions filed with the SEC under this name, the latest on Nov 14, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
21
Companies involved
3
Oramed PharmaceuticalsORMP
18 disclosures · Jan 2026 – Nov 2026
Nov 12, 2026629Kdisclosed Nov 14
DetailsOfficial recordNov 12, 2026688Kdisclosed Nov 14
DetailsOfficial recordSep 24, 2026349Kdisclosed Sep 25
DetailsOfficial recordSep 24, 2026369Kdisclosed Sep 25
DetailsOfficial recordSep 24, 2026197Kdisclosed Sep 25
DetailsOfficial recordSep 24, 2026190Kdisclosed Sep 25
DetailsOfficial recordSep 24, 202649Kdisclosed Sep 25
DetailsOfficial recordSep 24, 202697Kdisclosed Sep 25
DetailsOfficial recordSep 24, 2026150Kdisclosed Sep 25
DetailsOfficial recordSep 24, 2026107Kdisclosed Sep 25
DetailsOfficial recordMar 30, 202645Kdisclosed Mar 31
DetailsOfficial recordMar 17, 2026167Kdisclosed Mar 18
DetailsOfficial recordMar 12, 2026100Kdisclosed Mar 16
DetailsOfficial recordJan 22, 2026109Kdisclosed Jan 29
DetailsOfficial recordJan 22, 2026109Kdisclosed Jan 29
DetailsOfficial recordDec 31, 2025233Kdisclosed Jan 5
DetailsOfficial recordDec 31, 2025327Kdisclosed Jan 5
DetailsOfficial recordDec 31, 2025109Kdisclosed Jan 5
DetailsOfficial recordNano DimensionNNDM
2 disclosures · Aug 2026
Aug 21, 202610Kdisclosed Aug 25
DetailsOfficial recordAug 21, 2026100disclosed Aug 25
DetailsOfficial recordLifewardLFWD
Mar 25, 20267,657disclosed Mar 27
DetailsOfficial recordNadav Kidron bought shares on the open market in 2015, 2016, 2018 and 2023, and has not bought since 2023. Sales in 2 of the 12 years since 2015.
Nadav Kidron reported 16 open-market purchases and 2 sales since 2015; purchases in 4 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $254K2×2 trades | — |
| 2021 | — | $4.42M1×1 trade |
| 2018 | $7221×1 trade | $3651×1 trade |
| 2016 | $7K4×4 trades | — |
| 2015 | $14K9×9 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Nadav Kidron reported holding 5,457,505 shares of Oramed Pharmaceuticals (ORMP), worth about $19.5M at the last close of $4 (Nov 20, 2026). Holdings are also on file at Nano Dimension (NNDM), Lifeward (LFWD); together they are worth about $19.5M.
Oramed Pharmaceuticals's proxy statement reports total compensation of $4.77M for Nadav Kidron for fiscal year 2025, after $2.1M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Aug 3, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals ORMP | 5,457,505 | 5.46M direct | $4 | $19.5M | Nov 12, 2026 |
| Nano Dimension NNDM | 30,000 | 30K direct | $1 | $32K | Aug 21, 2026 |
| Lifeward LFWD | 7,657 | 7,657 direct | $3 | $21K | Mar 25, 2026 |
Is this Nadav Kidron’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 12, 2026, Nadav Kidron reported holding 5,457,505 shares of Oramed Pharmaceuticals (ORMP). At the last close of $4 on Nov 20, 2026, that is about $19.5M. This is the stake disclosed in filings, not a net worth.
No public filing gives Nadav Kidron's net worth. What SEC Form 4 shows is the stock stake: 5,457,505 shares of Oramed Pharmaceuticals (ORMP), about $19.5M at the last close, plus holdings in 2 other companies, about $19.5M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Oramed Pharmaceuticals's proxy statement reports total compensation of $4.77M for Nadav Kidron for fiscal year 2025, after $2.1M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Nadav Kidron bought shares on the open market in 2015, 2016, 2018 and 2023, and has not bought since 2023. Sales in 2 of the 12 years since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2023; the latest open-market sale is from 2021.
Oramed Pharmaceuticals (ORMP), from 2015 to 2023: 16 purchases and 2 sales.
Nadav Kidron reported 16 open-market purchases and 2 sales here, 2015 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.